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The March 11 earthquake and tsunami in Japan
has caused the worst radiation disaster since Cher-
nobyl. In the ensuing weeks, dozens of workers have
been exposed to radiation while struggling to limit
the release of radioactivity from damaged reactor con-
tainment vessels and compromised spent-fuel storage
pools. Fortunately, no serious immediate injuries have
been reported.
Exposure monitoring for individual workers en-
ables managers to limit radiation doses, and this
relatively controlled situation should prevent, bar-
ring further calamity, any dangerous exposures. Nev-
ertheless, some medical professionals including
a group of experienced hematologists in Japan advis-
ing on safety measures for this catastrophic situation
have proposed that, because the bone marrow is
known to be the most radiosensitive organ in the
body, hematopoietic progenitor and stem cells
(HPC) should be collected prophylactically from
some or all workers [1]. Then, if a subsequent un-
controlled radiation exposure occurred, a worker
who received a marrow-ablative dose of radiation
could be rescued with an infusion of his own (autol-
ogous) cells.
Autologous HPC transplantation has been used
therapeutically to treat various cancers for more than
30 years. The procedure makes it possible to deliver
otherwise lethal doses of radiation and/or chemother-
apy to the cancer and achieve higher tumor cell kill. It
works, and works very well. Countless cancer survivors
can attest to its effectiveness and safety. But this is
a finely tuned delivery of cytotoxic therapy: too little
and the autologous HPC are irrelevant; too much
and the toxicities to other organs (gut, lung, blood ves-
sels, brain) prove fatal [2]. It is estimated that exposures
of whole-body irradiation 4 to 9 Gy (4000-9000 mSv)
fall in this range where marrow suppression is the
critical factor for survival, but partial-body irradiation,
as might occur with workers partially shielded by
walls or equipment, may spare some marrow tissue
allowing spontaneous hematologic recovery [3-5].
For radiation casualties without radiation monitors,
the ability to assign precise radiation dose to each
organ is not possible today. Victims with even severe
exposures can be medically supported for weeks
to months if autologous recovery is possible, but
transplantation of HPC for selected cases could
accelerate recovery [6].
So, what is the likelihood that a worker in the
Fukushima Daiichi nuclear plant will receive that
precise dose of radiation that will render autologous
HPC rescue a necessary and life-saving procedure?
We do not know, but it is probably very low.
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sion, it is estimated that tens of thousands might be
exposed to major doses of radiation [7]. Among these,
there could be hundreds or thousands who receive that
precise dose wherein marrow destruction is a certainty,
but no other organ is irreversibly injured. These
victims could conceivably be saved with HPC rescue.
But we certainly cannot store autologous cells on
every potential victim in major U.S. cities. If victims
in this terrible scenario can be rescued with HPC,
they will be rescued with donated (allogeneic) HPC
from HLA (human leukocyte antigen)-matched rela-
tives, volunteer unrelated donors, or frozen umbilical
cord blood units from public cord blood banks [8,9].
In the United States, we have established the Radiation
Injury Treatment Network (RITN) (www.ritn.org),
a collaboration of the American Society for Blood
and Marrow Transplantation (www.ASMBT.org)
and the National Marrow Donor Program (NMDP),
which in coordination with U.S. government and
regional emergency planning programs has plans
and procedures for such urgent situations. RITN
members include Bone Marrow (HPC) transplant
programs plus the marrow, blood stem cell, and
umbilical cord bank donor network (www.marrow.org).
Transplant physicians understand bone marrow
suppression. We know how to manage patients with
marrow injury. We can identify those that need
allogeneic HPC infusions for rescue and we can
recognize multiorgan injury that is unrecoverable.
RITN has also established guidelines for advanced
planning to outline steps in evaluation of those with
marrow injury, shared tools to estimate radiation
exposure, supportive care management techniques,
and procedures to provide multifaceted treatments
for marrow suppressed radiation victims. For some,
whose radiation exposure falls in the window of
severe marrow injury without otherwise lethal organ
toxicity, aggressive supportive care may not be
enough. Then HPC replacement with autologous
(if available) or more likely, allogeneic donor cells, may
be needed. Plans and protocols for such treatments
have been proposed.
We emphasize that in some, likely limited circum-
stances, autologous HPC collection and cryopreserva-
tion may be appropriate, but careful analysis suggests
that very few victims might either need or benefit
from such preemptive measures. In a large scale, unan-
ticipated accidental or terrorist radiation incident,
autologous HPC will not be available or applicable
to the broader public exposed to radiation. Alterna-
tively, education and planning for management of
the acute radiation syndrome, prompt application of
clinical or laboratory dose estimation algorithms, and
administration of marrow-stimulating cytokines or
other radiation injury mitigators may be of equal or
greater benefit, especially for a large-scale incident.
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with allogeneic matched hematopoietic cells could be
their best option. Ongoing support for research into
new dosimetry techniques and radiation mitigators
along with better medical management approaches
could expand the array of useful options to help
victims: whether few or many.
We also recognize that our U.S. and collaborating
overseasnetworkofphysicians is small, capableof a lim-
ited supportive role for a contained number of victims:
such as could have occurred with the recent industrial
accident. But the only way that RITN can effectively
respond to the unfathomable nuclear explosion is
when physicians everywhere devote their efforts to un-
derstanding radiation and how to manage its effects.ACKNOWLEDGMENT
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